Increlex (Mecasermin)

Mecasermin is a recombinant form of human insulin‑like growth factor‑1. It binds to IGF‑1 receptors on cells, activating signaling pathways that promote protein synthesis and cell proliferation, especially in growth plates of bones. This mimics the natural growth‑promoting effects of endogenous IGF‑1.

The dose of Increlex is individualized. A qualified prescriber determines the appropriate amount based on the child’s age, weight, IGF‑1 levels, and clinical response. Dosing is typically started low and titrated to achieve desired growth outcomes while monitoring safety.

Safety data for Mecasermin in pregnant or nursing women are limited. It is generally recommended to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk. Physicians should discuss individual circumstances with patients.

To order Increlex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Increlex provides direct IGF‑1 replacement, whereas traditional growth‑hormone therapy supplies GH that the body converts to IGF‑1. For patients lacking IGF‑1 production or with GH gene deletions, Mecasermin is the preferred option because it bypasses the need for functional GH secretion.

Increlex should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside this range.

Increlex is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce local reactions. Administration is performed by a trained caregiver or healthcare professional according to the prescriber’s instructions.

Serious risks include severe hypoglycemia, intracranial hypertension, slipped capital femoral epiphysis, and potential acceleration of pre‑existing malignancies. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Increlex is contraindicated in patients with active malignancies, known hypersensitivity to Mecasermin or any excipients, and in children whose growth failure is not due to IGF‑1 deficiency. It should also be used with caution in those with uncontrolled diabetes or severe hypoglycemia risk.